{"id":411572,"date":"2021-01-11T05:02:38","date_gmt":"2021-01-11T10:02:38","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=411572"},"modified":"2021-01-11T05:02:38","modified_gmt":"2021-01-11T10:02:38","slug":"dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\/","title":{"rendered":"Dr. Reddy’s Laboratories announces the launch of Febuxostat Tablets in the U.S. Market"},"content":{"rendered":"

<\/p>\n

Dr. Reddy’s Laboratories announces the launch of Febuxostat Tablets in the U.S. Market<\/b><\/p>\n

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE<\/a>)–
\nDr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) today announced the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) Tablets approved by the U.S. Food and Drug Administration (USFDA).\n<\/p>\n

\nThe Uloric brand and generic had U.S. sales of approximately $108million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health*.\n<\/p>\n

\nDr. Reddy\u2019s Febuxostat Tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets.\n<\/p>\n

\nPlease see the full prescribing information including boxed warning.
\n
https:\/\/www.drreddys.com\/pi\/febuxostat_tablets.pdf<\/a><\/p>\n\n\n
\n

\n\u00a0\n<\/p>\n

WARNING: CARDIOVASCULAR DEATH<\/b><\/p>\n

\n\u00a0\n<\/p>\n

\nGout patients with established cardiovascular (CV) disease treated with Febuxostat had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study [see Warnings and Precautions (5.1)].\n<\/p>\n

\n\u00a0\n<\/p>\n

\nConsider the risks and benefits of Febuxostat when deciding to prescribe or continue patients on Febuxostat. Febuxostat should only be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable [see Indications and Usage (1)].\n<\/p>\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nUloric is a trademark of TEIJIN KABUSHIKI KAISHA (TEIJIN LIMITED)
\n<\/a>
*IQVIA Retail and Non-Retail MAT October 2020.
\n
RDY-0121-323\n<\/p>\n

About Dr. Reddy\u2019s<\/b>: Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products \u2013 Dr. Reddy\u2019s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy\u2019s operates in markets across the globe. Our major markets include \u2013 USA, India, Russia & CIS countries, and Europe. For more information, log on to:www.drreddys.com<\/a><\/p>\n

\nDisclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management\u2019s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency \/ severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and\/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, <\/span><\/b>and (vi) the susceptibility of our industry and the markets addressed by our, and our customers\u2019, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the “Risk Factors” and “Forward-Looking Statements” sections of our Annual Report on Form 20-F for the year ended March 31, 2020. The company assumes no obligation to update any information contained herein.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210111005471\/en\/<\/a><\/span><\/p>\n

INVESTOR RELATIONS
\n<\/b>
AMIT AGARWAL
\n
amita@drreddys.com
\n<\/a>
<\/span>(PH: +91-40-49002135)\n<\/p>\n

MEDIA RELATIONS
\n<\/b>
APARNA TEKURI
\n
aparnatekuri@drreddys.com
\n<\/a>
(PH: +91-40-49002446)\n<\/p>\n

KEYWORDS:<\/b> New York New Jersey United States India North America Asia Pacific<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology FDA Pharmaceutical Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Dr. Reddy’s Laboratories announces the launch of Febuxostat Tablets in the U.S. Market HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)– Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) today announced the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) Tablets approved by the U.S. Food and Drug Administration (USFDA). The Uloric brand and generic had U.S. sales of approximately $108million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health*. Dr. Reddy\u2019s Febuxostat Tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets. Please see the full prescribing information including boxed … <\/p>\n

Continue reading “Dr. Reddy’s Laboratories announces the launch of Febuxostat Tablets in the U.S. Market”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-411572","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nDr. Reddy's Laboratories announces the launch of Febuxostat Tablets in the U.S. Market - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dr. Reddy's Laboratories announces the launch of Febuxostat Tablets in the U.S. Market - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dr. Reddy’s Laboratories announces the launch of Febuxostat Tablets in the U.S. Market HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)– Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) today announced the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) Tablets approved by the U.S. Food and Drug Administration (USFDA). The Uloric brand and generic had U.S. sales of approximately $108million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health*. Dr. Reddy\u2019s Febuxostat Tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets. Please see the full prescribing information including boxed … Continue reading "Dr. Reddy’s Laboratories announces the launch of Febuxostat Tablets in the U.S. Market"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-11T10:02:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210111005471r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dr. Reddy’s Laboratories announces the launch of Febuxostat Tablets in the U.S. Market\",\"datePublished\":\"2021-01-11T10:02:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\\\/\"},\"wordCount\":677,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210111005471r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\\\/\",\"name\":\"Dr. Reddy's Laboratories announces the launch of Febuxostat Tablets in the U.S. Market - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210111005471r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-01-11T10:02:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210111005471r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210111005471r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dr. Reddy’s Laboratories announces the launch of Febuxostat Tablets in the U.S. Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dr. Reddy's Laboratories announces the launch of Febuxostat Tablets in the U.S. Market - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\/","og_locale":"en_US","og_type":"article","og_title":"Dr. Reddy's Laboratories announces the launch of Febuxostat Tablets in the U.S. Market - Market Newsdesk","og_description":"Dr. Reddy’s Laboratories announces the launch of Febuxostat Tablets in the U.S. Market HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)– Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) today announced the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) Tablets approved by the U.S. Food and Drug Administration (USFDA). The Uloric brand and generic had U.S. sales of approximately $108million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health*. Dr. Reddy\u2019s Febuxostat Tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets. Please see the full prescribing information including boxed … Continue reading \"Dr. Reddy’s Laboratories announces the launch of Febuxostat Tablets in the U.S. Market\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-11T10:02:38+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210111005471r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dr. Reddy’s Laboratories announces the launch of Febuxostat Tablets in the U.S. Market","datePublished":"2021-01-11T10:02:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\/"},"wordCount":677,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210111005471r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\/","name":"Dr. Reddy's Laboratories announces the launch of Febuxostat Tablets in the U.S. Market - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210111005471r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-01-11T10:02:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210111005471r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210111005471r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-febuxostat-tablets-in-the-u-s-market\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dr. Reddy’s Laboratories announces the launch of Febuxostat Tablets in the U.S. Market"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=411572"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411572\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=411572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=411572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=411572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}